CoChat

Ligand‐directed signalling at β‐adrenoceptors

Open access
Evans, Bronwyn A., Sato, Masaaki, Sarwar, Mohsin, Hutchinson, Dana S., Summers, Roger J. · 2010 · British Journal of Pharmacology
Cited by 153

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

β‐Adrenoceptors (ARs) classically mediate responses to the endogenous ligands adrenaline and noradrenaline by coupling to Gsα and stimulating cAMP production; however, drugs designed as β‐AR agonists or antagonists can activate alternative cell signalling pathways, with the potential to influence clinical efficacy. Furthermore, drugs acting at β‐ARs have differential capacity for pathway activation, described as stimulus trafficking, biased agonism, functional selectivity or ligand‐directed signalling. These terms refer to responses where drug A has higher efficacy than drug B for one signalling pathway, but a lower efficacy than drug B for a second pathway. The accepted explanation for such responses is that drugs A and B have the capacity to induce or stabilize distinct active conformations of the receptor that in turn display altered coupling efficiency to different effectors. This is consistent with biophysical studies showing that drugs can indeed promote distinct conformational states. Agonists acting at β‐ARs display ligand‐directed signalling, but many drugs acting as cAMP antagonists are also able to activate signalling pathways central to cell survival and proliferation or cell death. The observed complexity of drug activity at β‐ARs, prototypical G protein‐coupled receptors, necessitates rethinking of the approaches used for screening and characterization of novel therapeutic agents. Most studies of ligand‐directed signalling employ recombinant cell systems with high receptor abundance. While such systems are valid for examining upstream signalling events, such as receptor conformational changes and G protein activation, they are less robust when comparing downstream signalling outputs as these are likely to be affected by complex pathway interactions. This article is part of a themed section on Molecular Pharmacology of GPCR. To view the editorial for this themed section visit http://dx.doi.org/10.1111/j.1476‐5381.2010.00695.x

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2009.00602.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 153

Metadata

Authors
Evans, B. A., Sato, M., Sarwar, M., Hutchinson, D. S., & Summers, R. J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2010-03
Volume
159
Issue
5
Pages
1022-1038
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1932343077
Cited by
153
References
4
FWCI
5.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ligand‐directed signalling at β‐adrenoceptors. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00602.x
The paper
Evans, B. A., Sato, M., Sarwar, M., Hutchinson, D. S., & Summers, R. J. (2010). Ligand‐directed signalling at β‐adrenoceptors. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00602.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.